TP And NP Regimen In Advanced Triple Negative Breast Cancer Analysis

Objective: The review analysis56example advanced three negative breast cancerpatients accept the TP plan and the NP plan treatment clinical curative effect and theuntoward effect separately.Methods: Altogether collects October,2005to December,2010in the Dalianthird People’s Hospital treatment later period three negative breast cancer patient56examples.27cases of patients receiving chemotherapy regimens of paclitaxel pluscisplatin, Specific programs: Paclitaxel135mg/㎡,d1; Cisplatin25mg/㎡d1-3,21days of a cycle.29cases of patients receiving vinorelbine plus cisplatinchemotherapy, specific programs: Vinorelbine25mg/㎡,d1,d8; cisplatin25mg/㎡d1-3,21days for a cycle. Evaluated after each group of patients are two–cycle,Weekly safety assessment. Paclitaxel in patients completed a total of122cycles,Patients at least accept every two cycle chemotherapy, the median chemotherapy cyclefor four cycles. Vinorelbine patients completed a total of118cycles, each patientreceived at least two cycles of chemotherapy, the median chemotherapy cycle for fourcycles. Observed two groups of patients with clinical efficacy and toxicity. Termevaluation according to RECIST solid tumor evaluation criteria. Adverse reactionaccording to WHO toxicity is divided into0-Ⅳ level standard.Results:56patients were evaluable for efficacy, the overall objective responserate(ORR) was53.6%, disease control rate(DCR) was75.0%. TP group and NP groupachieved complete remission (CR) were11.1%(3cases) and6.9%(2cases), partialremission (PR) were44.4%(12cases) and44.8%(13cases), Stable (SD) were22.2%(6cases) and20.7%(6cases), progression (PD) were22.2%(6cases) and27.6%(8cases), no significant difference (P>0.05). TP group and NP groupobjective remission rate was55.5%and51.7%, disease control rates77.8%and72.4%,the difference was not statistically significant (P>0.05). TP plan group of patients with disease progression of time of1.5-24months and the median time progress for eightmonths; NP plan group of patients with disease progression of time of1.5-20monthsand the median time progress of6.5months. TP group and NP group,1-year survivalrate was77.5%and82.8%, the difference was not statistically significant (P>0.05).TP in the treatment of always use anthracycline-based not on anthracycline-basedpatients effective rate of52.4%and66.7%, the difference was not statisticallysignificant; As of late treatment treated first and treat treatments effective rate of62.5%and45.5%, the difference was not statistically significant. NP in the treatment of alwaysuse anthracycline-based not on anthracycline-based patients effective rate of50.0%and60.0%, the difference was not statistically significant; As of late treatment treated firstand treat treatments effective rate of61.5%and43.8%, the difference was notstatistically significant. TP scheme has radiation treatment of patients with no radiationrate of66.7%and33.3%, the difference was statistically significant; Treatment singletransfer position and more parts of the efficient transfer patients with71.4%and50.0%,the difference was statistically significant. NP scheme has radiation treatment ofpatients with no radiation rate of64.7%and33.3%, the difference was statisticallysignificant; Treatment single transfer position and more parts of the efficient transferpatients with75.0%and52.9%, the difference was statistically significant.The two groups were the main toxicities were myelosuppression andgastrointestinal reactions, multi-grade Ⅰ-Ⅱ reaction, III-IV reaction less. Bonemarrow suppression mainly leukopenia. TP group and NP group leukopenia, nauseaand vomiting was85.2%and82.8%,85.2%and89.7%, no significant difference. TPgroup with damage to the liver function of the NP group, the occurrence ofnephrotoxicity was18.5%and17.2%,11.1%and10.3%, the difference was notstatistically significant.TP group and NP group, hair loss, muscle and joint pain,phlebitis, the incidence of cardiac toxicity were81.5%and51.7%,55.6%and6.9%,0%and34.5%,14.8%and0%, the difference statistically significant.Conclusion：1. A paclitaxel plus cisplatin, vinorelbine plus cisplatin for advancedtriple negative breast cancer, objective response rate was55.5%and51.7%, mediantime to progression of8months and6.5months, and have a better effect the two groupscan be as advanced triple negative breast cancer chemotherapy.2. TP and NP regimens for the past has been used or not used in patients withanthracycline, late beginning of treatment or retreatment of patients had a good effect,no significant differences. Treatment of multiple lesions in patients compared with single lesions in patients with poor efficacy. The treatment is not patients treated withradiotherapy compared with radiotherapy in patients with poor efficacy.3. TP group and NP group major adverse reactions were myelosuppression andgastrointestinal reactions, the TP group hair loss, muscle and joint pain, cardiactoxicity was significantly higher than the NP group, phlebitis of the NP program groupwas higher than TP group, two groups of patients with adverse reactions were tolerable.